Innovation in Natural, Clean Ingredients Ushers in Sensegen

Beautiful biotechnology meets the science of good sense

Rancho Santa Margarita, Calif., Feb. 15, 2022 (GLOBE NEWSWIRE) — Sensegen,  southern California’s new taste, smell, and beauty business, enters the ingredient market as the first 100% biotechnology-based solution provider serving these markets. Emerging as The Science of Good Sense™, Sensegen’s brand launch marks an 18-month incubation previously under the name Blue California Flavors and Fragrances.

“We’re charting our course in clean and sustainable taste, smell, and beauty in a new and exciting way,” said Kathy Oglesby, chief value creation officer. “Under one roof, perfumers, flavorists, biologists, and chemists are working together, inspired by nature, and disciplined by science.”

Collaborating in their modern and well-equipped Creative Center, the designers are market-focused on biotechnology-based ingredient solutions to design and customize clean-label collections. The Creative Center is full service and state-of-the-art in capability, housing flavor, fragrance, cosmetic, and personal care creation teams supported by analytical chemistry, applications development, and sensory science teams.

Taste, smell, and beauty brands are encouraged to peruse Sensegen’s new website sensegen.com to gain insight into Sensegen’s collections, provenance, philosophy, biobased technology, sensible ingredient innovation process, transparent business practices, and sustainability position.

“Sensegen is committed to supporting brands to meet consumers’ expectations of reducing the environmental footprint of their products and inspiring repeat purchases,” said Oglesby. “We are 100% focused on true-to-nature, sustainable, and clean ingredients made possible by biotechnology.”

Oglesby further states, “The beauty of biotech in ingredient creation is monumental. It is significantly more sustainable than agriculturally derived and petroleum-based ingredients.”

Consumers are seeking to buy clean and sustainable products, and they are expecting companies to change from synthetic to natural. In an Edelman Trust survey, consumers confirmed that they expect companies and business leaders to address and solve macro socio-environmental challenges. And in a 2020 World Economic Forum survey, it appears evident that many are willing to participate actively in building back a better world alongside the brands they choose. In responses from 21,000 people and 28 countries, the survey reported that 86% want to see more sustainable and equitable products in the post-pandemic market.

“Sensegen’s launch marks our commitment to The Way Forward™ – an evolving journey to reinvent natural taste, smell, and beauty solutions,” said Oglesby. “Always customer-focused, our disruptive and provocative business model is based on co-creation, transparency, and partnering to produce clean-label solutions that are easy on the planet.”

Disruptive innovations to date include plant-based musk – one of the fragrance industry’s favorite types of materials. Plantarome™ M  is the first biotech source of musk, a highly strategic option for the market with natural animal sources unethical to harvest and, plant sources too costly for mainstream use. Other musk offerings are synthetic, many of which have already been banned in major markets or are limited in concentration due to safety concerns.

The fermentation and bioconversion processes of innovation partner, Conagen, produce optically active molecules that are precisely what nature makes. “Our innovation partnership with Conagen, where there is a natural flow of creativity and intelligence between market and science, creates great value for us and for our customers,” said Oglesby. “And our market success and expansion into beauty demonstrates it.”

Another advantage of biotechnology-based ingredients is that they can sidestep wobbles in supply chains caused by poor weather, seasonality, and inconsistent plant harvest quality without resorting to synthetic substitutes.

Oglesby foresees, “What we created in 2021 with Conagen is a prelude to the great achievements that will be revealed in 2022.”

Sensegen’s new market focus is evolving into three pillars:

The extensive portfolio of true-to-nature liquid flavors will be expanded in 2022 to include powders and new delivery as the tonality excellence will be applied to other sweet flavors and plant-based offerings.

  • Smell (Air Care, Home Care, Fabric Care, Personal Care, and Fine Fragrance)

New captives form the basis for the growing collection of “the new naturals” for fragranced consumer products. Sensegen’s fragrances fill a white space for naturals in the fragrance market moving toward today’s synthetics in both variety and technical performance.

  • Beauty (Personal Care, Hair and Skin Care, and Cosmetics)

Coming soon is a line of clean, novel, proprietary offerings as well as natural and sustainable qualities of market favorites.

“We’re driving the pipeline of taste, smell, and beauty into the 21st century with the guidance of nature and science, driven by the ‘savoir faire’ of the fragrance, flavor, and cosmetic industries,” concluded Oglesby.

About Sensegen

Sensegen™, is the science of good sense. We’ve got nature down to a science.

As a division of Blue California Ingredients, our innovative taste, smell, and beauty creative center is dedicated solely to delivering plant-based, natural, and sustainable solutions. Our diverse team of experts collaborate with advanced bio-techniques and collaborate as a team to provide unique consumer-validated ingredients.

At Sensegen™, we’ve pioneered a way of formulating nature without compromise or harm; providing one-of-a-kind solutions for Taste, Smell, and Beauty.

Attachments

Ana Arakelian, Head of Public Relations and Communications
Sensegen
+1.949.635.1991
pr@sensegen.com

Saudi Arabia Records Increase in the Recruitment Contracts of Domestic Workers in 2021

Recruitment from several New Countries Added in 2022

RIYADH, Saudi Arabia, Feb. 12, 2022 /PRNewswire/ — According to “Musaned” platform of the Saudi Ministry of Human Resources and Social Development, which is specialized in the recruitment of domestic workers, the Kingdom of Saudi Arabia recorded an increase in the total recruitment contracts of domestic workers during the fourth quarter of the year 2021, where the rate of increase between October and December reached more than 15%.

Saudi Arabia is utilizing “Musaned” platform to add several new countries to the recruitment of workers in the current year 2022. The Kingdom is also keen to have the domestic workers exported from the new countries fit the Saudi family, based on several studies and criteria, including: epidemics, crime rate, language, educational level, expected recruitment cost, salaries, and other criteria.

The platform indicated that the recruitment contracts of the domestic workers recorded an increase during the fourth quarter of the last year by amounting to 65,000 contracts in October, rising in November to more than 69,000 contracts, while in December they exceeded the ceiling of 76,000 contracts, thus recording a steady increase in the number of recruitment contracts at the end of 2021.

“Musaned” platform indicated that Bangladesh topped the list of countries with the highest domestic workers recruitment contracts during the month of December of the year 2021 with more than 12 thousand contracts, while Pakistan came second with more than 11 thousand contracts, followed by the India with about 11 thousand contracts. The latter recorded in December a higher turnout in issuing contracts compared to the months of October and November.

Based on the November records, Philippines recorded 13,000 recruitment contracts, followed by the Bangladesh with 13,000 contracts, and Egypt with more than 9,000 contracts. Philippines recorded the same figure of 13,000 contracts in October, while the number from Bangladesh rose to more than 11,000 contracts, and Uganda ranked third with about 10,000 contracts.

It is worth noting that “Musaned” platform aims to govern, automate and facilitate the procedures of the recruitment of domestic workers and increase the level of protection of the rights of all parties by managing the contracting process between individuals and the recruitment offices, in addition to the management of the relationship between the Saudi recruitment offices and the domestic workers offices in the workers exporting countries.

Adagio Therapeutics Announces Expansion of Patient Population in Global Phase 2/3 Clinical Trial of ADG20 for the Prevention of COVID-19

Independent Data Monitoring Committee Supports Expansion to Adolescents and Pregnant and Nursing Women Based on Safety and Tolerability Data from Phase 2 Lead-In

WALTHAM, Mass., Sept. 10, 2021 (GLOBE NEWSWIRE) — Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced that the independent data monitoring committee (IDMC) for the EVADE Phase 2/3 trial of ADG20 for the prevention of COVID-19 has provided a recommendation to expand Phase 3 trial enrollment to include adolescents and pregnant or nursing women, as well as to decrease the protocol-specified, post injection monitoring time. The IDMC’s assessments are based on their review of unblinded safety and tolerability data from 200 participants enrolled in the Phase 2 lead-in portion of the trial. Adagio remains blinded to the data and plans to implement the IDMC recommendations for the Phase 3 portion of the trial. EVADE is being conducted globally, including in regions where there is a high prevalence of SARS-CoV-2 variants of concern, to evaluate the ability of a single, intramuscular dose of ADG20 to prevent COVID-19 in both pre- and post-exposure settings.

“Given the urgent need for additional treatment and preventative options for COVID-19, particularly in vulnerable populations, we are pleased that an independent assessment of the safety data from the lead-in portion of EVADE supported inclusion of adolescents and pregnant or nursing women in the next phase of the study,” said Lynn Connolly, M.D., Ph.D., chief medical officer of Adagio. “Based on the potent and broad activity of ADG20 in non-clinical studies, as well as its extended half-life and ease of administration, we believe this antibody has the potential to become a preferred prophylactic option for COVID-19, particularly for vulnerable groups such as children and the immunocompromised, for whom there are currently limited or no available options.”

The EVADE trial is a global, multi-center, double-blind, placebo-controlled clinical trial evaluating ADG20 in two independent cohorts. The first cohort (post-exposure prophylaxis) is designed to assess the safety and efficacy of ADG20 compared to placebo for the prevention of COVID-19 after exposure to an individual with laboratory confirmed SARS-CoV-2 infection. The second cohort (pre-exposure prophylaxis) is designed to assess the efficacy and safety of ADG20 compared to placebo in individuals who are at increased risk for SARS-CoV-2 infection due to occupational, housing or recreational situations, and in individuals who are at increased risk of poor vaccine response, including individuals with compromised immune systems or other co-morbidities. The primary efficacy endpoint in both cohorts is the prevention of laboratory confirmed, symptomatic COVID-19. For more information on the EVADE trial, please visit https://clinicaltrials.gov/ct2/show/NCT04859517.

The clinical development program for ADG20 includes two additional trials: the ongoing Phase 1 clinical trial of ADG20 in healthy volunteers and the ongoing STAMP trial evaluating ADG20 as a treatment for high-risk individuals with mild or moderate COVID-19 (see clinicaltrials.gov).

About ADG20
ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses, is being developed for the prevention and treatment of COVID-19, the disease caused by SARS-CoV-2. ADG20 was designed and engineered to possess high potency and broad neutralization against SARS-CoV-2 and additional clade 1 sarbecoviruses, by targeting a highly conserved epitope in the receptor binding domain. ADG20 displays potent neutralizing activity against the original SARS-CoV-2 strain as well as all known variants of concern. ADG20 has the potential to impact viral replication and subsequent disease through multiple mechanisms of action, including direct blocking of viral entry into the host cell (neutralization) and elimination of infected host cells through Fc-mediated innate immune effector activity. ADG20 is formulated at high concentrations, enabling intramuscular administration, and was engineered to have a long half-life, with a goal of providing both rapid and durable protection. Adagio is advancing ADG20 through multiple clinical trials on a global basis.

About Adagio Therapeutics
Adagio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch. For more information, please visit www.adagiotx.com.

Contacts:
Media Contact:
Dan Budwick, 1AB
Dan@1abmedia.com

Investor Contact:
Monique Allaire, THRUST Strategic Communications
monique@thrustsc.com